Head-to-head evidence
ALZ-101 vs Donanemab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Alzheimer's Disease
Shared mechanism: Amyloid-beta (monoclonal antibody) · full Alzheimer's Disease pipeline
ALZ-101
Developed by Alzinova AB
NCT05328115 · Phase 1 · completed
Most of the trial was randomized and blinded against placebo, but the highest-dose group was given openly rather than blinded, and only 33 people took part. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Reports Part A of the trial (26 randomised participants), fewer than the trial's registered enrollment of 33.
Donanemab · Kisunla
Marketed by Eli Lilly
NCT05108922 · Phase 3 · completed
Participants were randomized to donanemab or active-control aducanumab, but the trial was open-label rather than blinded. Both prespecified primary amyloid-clearance comparisons favored donanemab with statistically significant results; the biomarker-based primary endpoint and lack of blinding support a moderate evidence grade rather than a strong one.
Next expected readout: November 2027 · NCT05026866 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ALZ-101's landscape · Donanemab's landscape